Q-omics provides the consensus-scored ELOCP19 profile across patient tissues and cancer cell-line models. ELOCP19 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ELOCP19 is differentially expressed in 10, with the highest sampling consensus in READ. Additionally, ELOCP19 RNA expression shows 19,092 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THCA, READ, and UVM as cancer lineages where ELOCP19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP19 survival associations across molecular data types. ELOCP19 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP19 RNA expression–survival associations across cancer types. High ELOCP19 expression shows unfavorable associations in THCA, LGG and KICH, but favorable associations in READ, HNSC and BRCA. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for ELOCP19 RNA expression.
This table summarizes ELOCP19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP19 shows lower tumor expression in READ, BRCA, THCA and KICH and higher tumor expression in BLCA and CHOL. The READ box plot shows higher ELOCP19 RNA expression in normal versus tumor tissue (log2 FC = −0.666, t-test p = .011).
This table shows molecular features associated with ELOCP19 in patient tissues and cancer cell lines. In patient samples, ELOCP19 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
